<DOC>
	<DOCNO>NCT00911339</DOCNO>
	<brief_summary>The purpose study evaluate extent mobilization endothelial progenitor cell induce low versus high dose atorvastatin 4 week treatment , patient treat anti-CD 34 antibody coat stent .</brief_summary>
	<brief_title>Mobilization Endothelial Progenitor Cells Induced Atorvastatin Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents</brief_title>
	<detailed_description>Addition statins peripheral blood circulate mononuclear cell ( PBMNCs ) CD 34+ subset culture promote endothelial progenitor cell ( EPCs ) proliferation , migration survival accord time concentration-dependent effect . Data suggest patient stable coronary artery disease atorvastatin 40 mg/day induce 2 fold increase number CD34+VEGFR2+ cell 1 week treatment 3 fold increase 4 week ; likewise , number EPCs colony increase 1.5 time 1 week 3 time 4 week . Data also suggest short term mobilize effect statin EPCs may transient medium-high dos long term statin treatment ( &gt; 1 month ) may lead reduction EPCs . Rather , depletion EPCs may explain exhausted mobilization also improve incorporation site tissue hypoperfusion potentially beneficial effect therapeutic angiogenesis.In interventional contest high concentration circulate EPCs may contribute accelerate reendothelialization process stent implantation coronary artery . Considering use recent stent coat anti-CD34 murine antibody , presence high level PBMNCs express CD34 surface antigen may define safety efficacy level procedure . Both angiographic outcome clinical outcome seem good patient normal level EPCs patient low level . No data available effect different dos statins biology PBMNCs particular timing mobilization , duration mobilization , CD 34+ cell subset subpopulation mobilize gene expression balance human . No data available effect statins clinical evolution patient treat PCI implantation stent coat anti-CD34 murine antibodies.no specific data describe effect different dos statins biology PBMNCs particular timing mobilization , duration mobilization , CD 34+ cell subset subpopulation mobilize gene expression balance human . No study evaluate effect statin clinical evolution patient treat PCI implantation new stent , coat anti-CD34 murine antibody . These data contribute good define process mobilization endothelial progenitor induce statin set best pharmacological strategy anti-CD34 coated stent deployment .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>age 18 75 year stable angina silent ischemia document CAD sign write informed consent current recent therapy ( stop &lt; 3 month ) statins allergy ASA ticlopidine/clopidogrel myocardial infarction ( &lt; 3 month ) recent significant trauma surgical intervention ( &lt; 3 mesi ) significant renal hepatic disease coagulativehematological disorder cancer inflammatory diseases myopathy pregnancy ( pregnancy test perform fertile woman ) severe coronary calcification , small vessel disease ( &lt; 2.5 mm ) , long lesion ( &gt; 20 mm ) , ostial lesion , bifurcation lesion request treatment collateral vessel , multivessel disease require PCI completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>